Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Biomarkers

Topic: Risk, prevention and care in population studies

Plain-language summary

Although recent studies have demonstrated the prognostic utility of plasma biomarkers of Alzheimer pathology or neurodegeneration, such as pTau-181 and NF-L, whether other plasma biomarkers can further improve prediction of cognitive decline is undetermined. We developed a machine learning model to distinguish progressors from stable and used 44 proteins with significantly different plasma levels in progressors versus stable along with age, sex, education and baseline cognition as candidate features. The Olink proteins selected by the model included those associated with vascular injury and neuroinflammation (e.g. The proteins NF-L and PTP-1B were significantly higher in both Alzheimer and non-Alzheimer dementias compared with cognitively normal individuals. In summary, our findings suggest that plasma biomarkers of inflammation and vascular injury are associated with cognitive decline. Developing a plasma biomarker profile could aid in prognostic deliberations and identify individuals at higher risk of dementia in clinical practice.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 60 participants. A machine learning model using plasma proteins linked to inflammation and vascular injury, along with age, sex, education and baseline cognition, was developed to distinguish people with mild cognitive impairment who progressed from those who stayed stable. Reported effect size: 86.7%; 78.6%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kivisäkk, P., Magdamo, C., Trombetta, B. A., Noori, A., Kuo, Y. K. E., Chibnik, L. B., et al. (2022). Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. Brain communications. https://doi.org/10.1093/braincomms/fcac155

Vancouver

Kivisäkk P, Magdamo C, Trombetta BA, Noori A, Kuo YKE, Chibnik LB, et al. Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. Brain communications. 2022. doi:10.1093/braincomms/fcac155. PMID: 35800899.

BibTeX

@article{kivisakk2022-35800899,
  author  = {Kivisäkk, P. and Magdamo, C. and Trombetta, B. A. and Noori, A. and Kuo, Y. K. E. and Chibnik, L. B. and Carlyle, B. C. and Serrano-Pozo, A. and others},
  title   = {{Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment}},
  journal = {Brain communications},
  year    = {2022},
  doi     = {10.1093/braincomms/fcac155},
  pmid    = {35800899},
  url     = {https://doi.org/10.1093/braincomms/fcac155}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

A machine learning model using plasma proteins linked to inflammation and vascular injury, along with age, sex, education and baseline cognition, was developed to distinguish people with mild cognitive impairment who progressed from those who stayed stable. This suggests a plasma profile could help predict cognitive decline, but it is a prognostic tool and not a treatment.

Study details

How this study scored 62/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 0 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 1 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 3 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 62 of 100.62 of 100 points earned38 not earned

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Brain communications)
Journal's citation record 0 / 4 Brain Communications: journal h-index 67 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 1 / 4 60 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 43 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.2 citations a year over 6 year(s) since 2022
Impact for its field and year 3 / 6 Cited 5.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 31 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Steven Edward Arnold: h-index 125 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 35800899)
Free to read 2 / 2 Free to read
Total 62 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →